Physician profile
Derrick J Plahn
NPI 1063650836
$2,874.41
in general payments reported to CMS, 2019-2025
23 companies · $672 in 2025
The $672 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $221 · 2021: $59.02 · 2022: $247 · 2023: $533 · 2024: $651 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,856.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $404.15 | 2019-2025 | Watchman Flx, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $400.37 | 2019-2025 | |
| Pfizer INC. | $295.24 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $285.54 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $285.37 | 2019-2025 | Farxiga, Brilinta |
| Novo Nordisk INC | $272.53 | 2023-2025 | Wegovy, Ozempic |
| Abiomed | $151.50 | 2023 | Impella |
| Merck Sharp & Dohme LLC | $150.54 | 2022-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $150.21 | 2019-2025 | Eliquis, Camzyos |
| Lexicon Pharmaceuticals, INC. | $131.49 | 2024 | Inpefa |
| Amgen INC. | $55.00 | 2019-2025 | Repatha |
| Cvrx, INC. | $52.46 | 2023 | Barostim Neo System |
| Abbott Laboratories | $40.02 | 2024-2025 | Mitraclip |
| Bridgebio Pharma, INC. | $39.82 | 2025 | Attruby |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.29 | 2020-2025 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $19.06 | 2025 | Zepbound, Mounjaro |
| Grifols USA, LLC | $18.76 | 2019 | |
| Amarin Pharma, INC. | $17.05 | 2021 | |
| Terumo Medical Corporation | $16.86 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $16.65 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $14.94 | 2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $13.57 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $12.99 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrick Plahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.